Project Details
Description
Assess the effectiveness of Alnylam’s neuronal targeted siRNA conjugates as therapeutic agents in in vivo glioma models. Experiments will evaluate efficiency of delivery and target gene knockdown in clinically relevant animal models of glioma. We will test multiple siRNA targets, which may include: CDK1, HIF1α, STAT3, Nucleolin, FGL2, and AKT1/2. Together, this information will provide the basis for defining additional target selection and therapeutic approaches for RNAi therapeutics in glioma.
| Status | Active |
|---|---|
| Effective start/end date | 9/1/22 → 8/31/23 |
Funding
- Alnylam Pharmaceuticals, Inc. (Signed 9/20/22)
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.